All In Biotech

Drug Trial Radar · NCT04308590

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients With Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant

Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 137 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

137

Actual

Start

Jul 27, 2020

Primary completion

Sep 19, 2024

Study completion Sep 19, 2024

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance (DM/IGT) and/or uncontrolled systolic hypertension (HTN).

Conditions

  • Hypercortisolism

Interventions

  • RelacorilantDrug

    Relacorilant is supplied as blister-packed capsules for oral dosing. Relacorilant 400 mg dose consists of 4 relacorilant 100-mg capsules. Relacorilant 100-mg, 200-mg, and 300-mg doses are each given as a combination of 4 capsules containing relacorilant 100-mg and placebo as per the assigned dose.

  • PlaceboOther

    Placebo is supplied as blister-packed capsules for oral dosing. Each dose consists of 4 capsules containing placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Average 24-hour SBPTime frame: Baseline and Week 22
  2. Number of Patients With 1 or More Treatment-emergent Adverse Events (TEAEs) as Graded by CTCAE v5.0.Time frame: Baseline and up to Week 26

Locations

45 sites in 9 countries. Site status is shown where the registry gives one.

  • Site 27

    Birmingham, Alabama

  • Site 17

    Stanford, California

  • Site 53

    Torrance, California

  • Site 07

    Atlanta, Georgia

  • Site 16

    Indianapolis, Indiana

  • Site 09

    Metairie, Louisiana

  • Site 36

    Baltimore, Maryland

  • Site 11

    Fall River, Massachusetts

  • Site 33

    Rochester, Minnesota

  • Site 06

    Jackson, Mississippi

  • Site 54

    Reno, Nevada

  • Site 10

    Jamaica, New York

  • Site 44

    New York, New York

  • Site 01

    Wilmington, North Carolina

  • Site 30

    Cleveland, Ohio

  • Site 21

    Columbus, Ohio

  • Site 02

    Summerville, South Carolina

  • Site 20

    Dallas, Texas

  • Site 03

    El Paso, Texas

  • Site 05

    Fort Worth, Texas

  • Site 08

    Houston, Texas

  • Site 15

    Spokane, Washington

  • Site 25

    Vienna, State of Vienna, Austria

  • Site 22

    Sofia, Bulgaria

  • Site 46

    Würzburg, Germany

  • Site 50

    Munich, Bavaria, Germany

  • Site 32

    Ramat Gan, Israel

  • Site 23

    Tel Aviv, Israel

  • Site 34

    Milan, Italy

  • Site 28

    Naples, Italy

  • Site 51

    Padova, Italy

  • Site 37

    Rome, Italy

  • Site 52

    Torino, Italy

  • Site 40

    Milan, Milano, Italy

  • Site 31

    Rome, Roma, Italy

  • Site 43

    Orbassano, Torino, Italy

  • Site 48

    Gliwice, Poland

  • Site 47

    Krakow, Poland

  • Site 35

    Lublin, Poland

  • Site 42

    Bucharest, Romania

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.